Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. - Wikidata - awgldk - TriplyDB

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

http://www.wikidata.org/entity/Q36801625

about

Epigenetic principles and mechanisms underlying nervous system functions in health and disease A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells Phenethylisothiocyanate alters site- and promoter-specific histone tail modifications in cancer cells Genome-wide demethylation by 5-aza-2'-deoxycytidine alters the cell fate of stem/progenitor cells.Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer.Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets.Linking yeast Gcn5p catalytic function and gene regulation using a quantitative, graded dominant mutant approach Manganese superoxide dismutase: beyond life and death Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation Dietary manipulation of histone structure and function.DNA demethylating antineoplastic strategies: a comparative point of view Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors Molecular targets for tumor radiosensitization.Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer.Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors.Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?Chromatin, cancer and drug therapies.Altered gene expression and miRNA expression associated with cancerous IEC-6 cell transformed by MNNG.The impact of genomics in understanding human melanoma progression and metastasis.Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma.The biology of cancer testis antigens: putative function, regulation and therapeutic potential Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy.Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.New therapeutic approaches to acute myeloid leukemia.Epigenetics of melanoma: implications for immune-based therapies.Oxidative stress, a common molecular pathway for kidney disease: role of the redox enzyme p66Shc.

P2860

Q24657549-FACC77F0-7DB6-4CAB-A4EF-869BE8AC663C Q26852571-D42A4DE2-944C-4001-A49C-8E0BABD7F403 Q28477278-32719D8C-AA80-4A2D-A246-695623D4D6A9 Q28533351-4E6F9192-0E5F-4884-8110-7E4A96314E89 Q30392550-5E87DA25-6AFE-42FC-833B-D38CBB264B2F Q30838169-DFDF0E6D-CF5F-4145-8964-FEF2A0E51A86 Q33653371-4625EEC4-3801-4396-80AD-5ADE7A2FEFB0 Q33802356-7BCBEF18-BD18-42DA-9223-DBF91D8A9892 Q33980682-13BB84A7-7EE9-4EF2-B684-BFC96A91F51C Q34075283-D806DDF4-69C7-49EB-A321-6CABC1F19102 Q34257296-97C46B4A-A7F9-40FC-AF07-064313C622EC Q34284548-8BDD7A8D-E62B-4D8A-9ED4-582C1AB670E6 Q34305840-65CDD3D8-4045-4E90-9B10-7A67D9C5BEDE Q34405013-44360583-7D0B-49CD-A844-C62FB4CB3694 Q34898711-BCEC8B37-D719-4247-94DB-2C283466FAE7 Q34972245-50CE186F-7D87-4339-BF57-571FE0F0972B Q35069309-C2A0FC80-1BE5-4393-BA81-35961FA22846 Q35556061-6C4C1A95-7671-4BA2-AF0C-352A1EFF8A31 Q35951090-55AC13B3-05FE-4B9F-B69E-6105316042C8 Q36126009-E0DFAC81-453F-45A1-8A63-8812C967E726 Q36287972-FD924ACB-3FB7-4E88-87E7-0765A610A0C5 Q36300261-9EE4716D-5A4D-4210-A489-09DA5DE81BEC Q36486116-746B6263-CE1C-4453-8E15-A67928B19819 Q36509433-027222EE-52A8-4E0E-A806-1E3F8BFA8E8F Q36517507-605C7DA3-D6B2-488B-A04E-71501F925097 Q36537920-BF2E009B-2518-49B1-BBFD-8084A38E43FB Q36938591-D41088F4-A45A-4EFA-B065-6E478F5A7FA9 Q36955099-6A2B5DE7-C200-49E4-93EA-1681D6EC8DC2 Q37025333-41F2BCEC-089F-4C6D-8A2D-C751C4B60060 Q37073231-E507FDFD-8D4C-45B5-9225-B88ACA1CF239 Q37184148-E8506CF4-F396-48E0-99CB-0EF6D622AB44 Q37205801-D99872D7-D722-408E-A397-6FF03C91D7E1 Q37219171-012BE957-0C60-48E1-BD82-0E2312753A29 Q37849976-7C6D03BD-3256-408D-87E3-068E6A79E12A Q37906461-EC278C49-D94F-42AA-AD9F-265EAE378230 Q37911312-37FB84D5-C6C9-49CC-A602-53373DDF7EA2 Q38075009-F8B84746-2655-4853-AB4C-85ABC71510CC Q38090673-56D10284-5257-44AD-B53D-5AD440D19BE6 Q38148588-A98B2F06-BF4C-4B4C-9E05-92C805F9795A Q38158050-14522E73-8171-4D02-88E5-B65528AB4282

P2860

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

http://www.wikidata.org/entity/Q36801625

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@ast

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@en

type

label

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@ast

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@en

prefLabel

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@ast

Epigenetic drugs as pleiotropi ...... cts and clinical applications.

@en

P1433

Q36801625-7E0B1C85-7859-4E31-9D48-A7EA073DB35D

P1476

Q36801625-57E6F2D8-E512-4E80-A665-34CD029CF015

P2093

Q36801625-1F132FB0-93A8-4483-AFDD-0671CA5B7B3B

Q36801625-2EF81214-E565-42C7-9AE4-E17A8B4285DC

Q36801625-6E5F4333-D827-4C34-9FBD-95E906EABB34

Q36801625-8EF78677-286A-4460-8A9A-3AD3318EE1E0

Q36801625-9CD81C38-3647-417B-B548-B3D34B70668A

Q36801625-B48D8F0D-E075-44CE-86E2-127F5C799B12

Q36801625-CCE6D594-8B10-41A1-A23E-3622DAA9447B

Q36801625-E3A6990D-82F5-41A6-B9CC-5C7608D8E8C2

P2860

Q36801625-05987F4B-60EB-4450-B3E7-E14D8A230F16

Q36801625-086DF80D-87E5-4FCE-A480-288D8945BB67

Q36801625-088EC8A2-2ED0-4898-A111-FC7DAA5841F9

Q36801625-08FFB4B0-105B-410B-8B9D-2B81D5293CF7

Q36801625-09637319-A13F-47E2-AD3A-6D5ABC32E7BD

Q36801625-0CCDCCE9-AE97-41E4-A0F9-92A27F265DA4

Q36801625-0E71A2A9-DEE6-4790-83A4-01D003433AAA

Q36801625-11A0D47E-A2B5-49CF-BF63-900DD8FAB4DA

Q36801625-12A0B99E-E928-4AF8-AD94-826703321079

Q36801625-15060CCB-D11A-453E-A935-44BC4EDEE58F

P304

Q36801625-FB67BDD4-94A6-4DE9-962A-3EECC052CBAB

P31

Q36801625-29E56617-5CCB-44ED-A798-15FA51B336EE

P356

Q36801625-0FFC7338-928C-486B-8ECC-3E4A13ACE2CE

P433

Q36801625-44FE55AA-2609-4E98-857E-8D94A56B8147

P478

Q36801625-961C32CB-DBD2-44AD-A277-C01D5A8466E9

P50

Q36801625-3044150B-0862-4F15-8088-12B166250B4E

Q36801625-42B28886-23FB-4109-BD05-5E3771648E90

Q36801625-981D8DA9-90B2-41FC-8D6C-6C160B71F920

Q36801625-9EB61020-B943-4079-A3CF-12279C436DE4

Q36801625-CACF7E61-8331-4B03-ACAA-F64070A7A3CD

Q36801625-EEC5C6A8-DF18-407B-8D10-798EDEDE52A4

P577

Q36801625-65D6698F-1FDE-439F-A37A-E278F09547C6

P5875

Q36801625-388D259D-49AC-49F6-B259-3742F47A763D

P698

Q36801625-FDFACBBB-EBF6-40DD-B151-3B10EBA530A6

P356

P1433

Journal of Cellular Physiology

P1476

Epigenetic drugs as pleiotropi ...... ects and clinical applications

@en

P2093

Anna Maria Di Giacomo

http://www.w3.org/2001/XMLSchema#string

Enzo Cortini

http://www.w3.org/2001/XMLSchema#string

Ester Fonsatti

http://www.w3.org/2001/XMLSchema#string

Francesca Colizzi

http://www.w3.org/2001/XMLSchema#string

Laura Pezzani

http://www.w3.org/2001/XMLSchema#string

Luca Sigalotti

http://www.w3.org/2001/XMLSchema#string

Lucia Anzalone

http://www.w3.org/2001/XMLSchema#string

Maresa Altomonte

http://www.w3.org/2001/XMLSchema#string

P2860

Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A.

CpG methylation, chromatin structure and gene silencing-a three-way connection.

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

The language of covalent histone modifications

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Effects of methylation on expression of TMS1/ASC in human breast cancer cells

Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

P304

330-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.21066

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

212

http://www.w3.org/2001/XMLSchema#string

P50

Elisabetta Fratta

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6370088

http://www.w3.org/2001/XMLSchema#string

P698

17458893

http://www.w3.org/2001/XMLSchema#string